Publications by authors named "Siham Bchir"

Claim this Profile
A
A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.
James D Campbell, Sandeep Gupta, Mandeep Singh Dhingra, Betzana Zambrano, Lucia Gan

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.
Sandra Villagomez-Martinez, Susanna Kharit, Anna Galustyan, Betzana Zambrano, Mandeep Singh Dhingra

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection.
Kerry J Laing, Anton M Sholukh, Kellie J MacPhee, Christopher L McClurkan, Anke Pagnon, Siham Bchir

Vaccine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial.
Federico Martinon-Torres, Miia M Virta, Susanna Koski, Ignacio Salamanca de la Cueva, Henryk T Szymanski

Infect Dis Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.
Laurent Coudeville, Isabelle Bertrand-Gerentes, Céline Zocchetti, Edith Langevin, Siham Bchir

Sci Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
Javier Díez-Domingo, Róbert Simkó, Giancarlo Icardi, Chan Poh Chong, Céline Zocchetti, Siham Bchir

Infect Dis Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after priming.
James Peterson, Katherine Galarza, Siham Bchir, Celine Zocchetti, Isabelle Bertrand-Gerentes

Pediatr Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children.
Federico Martinón-Torres, Robert Simko, Rolf Ebert, Mika Rämet, Céline Zocchetti, Siham Bchir

Infect Dis Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
Javier Díez-Domingo, Róbert Simkó, Giancarlo Icardi, Chan Poh Chong, Céline Zocchetti, Siham Bchir

Infect Dis Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Direct and indirect impacts of the COVID-19 pandemic on operational conduct of pediatric vaccine clinical trials".
Monica Anne McArthur, Siham Bchir, Estelle Dubois, Lucia Gan, Eric Gerchman

Hum Vaccin Immunother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
Markus Knuf, Mika Rämet, Nina Breinholt Stærke, Isabelle Bertrand-Gerentes, Yaël Thollot

Hum Vaccin Immunother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration.
Shabir A Madhi, Pío López, Betzana Zambrano, Emilia Jordanov, Siham B'Chir

Hum Vaccin Immunother· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
Federico Martinón-Torres, Javier Diez-Domingo, Emmanuel Feroldi, Emilia Jordanov, Siham B'Chir

Pediatr Infect Dis J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
Roman Prymula, Dorothee Kieninger, Emmanuel Feroldi, Emilia Jordanov, Siham B'Chir

Pediatr Infect Dis J· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months.
Pope Kosalaraksa, Kulkanya Chokephaibulkit, Suwat Benjaponpitak, Chitsanu Pancharoen, Sunate Chuenkitmongkol

Hum Vaccin Immunother· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) following primary series administration at 2, 4, 6 months of age in Latin America.
Eduardo Santos-Lima, Siham B'Chir, Andrew Lane

Vaccine· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis